Home>Topics>Companies>Synthes Holding AG

Synthes Holding AG

  1. All
  2. Commentary
  3. Headlines
  1. Update: Johnson & Johnson Facing New Lawsuits On Pinnacle Hips

    Headlines

    Wed, 3 Sep 2014

    By Andy Batts : Johnson & Johnson (NYSE: JNJ ) is facing a new round of lawsuits over its DePuy ..... claims that 8,000 of its artificial hips were defective. DePuy Synthes ' Pinnacle hip was allegedly defectively designed and caused metal

  2. Update: Johnson & Johnson Received FDA's Class I Label For Jaw-Stabilizing Device

    Headlines

    Tue, 2 Sep 2014

    By Andy Batts : Johnson & Johnson 's (NYSE: JNJ ) orthopedics-focused subsidiary DePuy Synthes unit is facing the FDA's ire as the regulator slapped the company's recall of its jaw-stabilizing device with highest-risk

  3. J & J unit recalls orthopedic implant

    Headlines

    Thu, 28 Aug 2014

    Johnson & Johnson 's ( JNJ -0.3% ) DePuy Synthes unit recalls certain lots of its Craniomaxillofacial Distraction System also called External Mandibular Fixator and/or Distractor

  4. Tides Turn for These Orthopedic Firms

    Headlines

    Mon, 30 Jun 2014

    competition should help the large, top-tier firms, including Johnson & Johnson JNJ, Zimmer, and Stryker SYK. However, this dynamic will ..... along with the most extensive trauma portfolio thanks to the Synthes acquisition), and then Biomet to make a vocal minority

  5. Medtronic to Buy Covidien, Redomicile in Ireland

    Commentary

    Mon, 16 Jun 2014

    allows it to free up cash trapped overseas. Johnson & Johnson 's acquisition of Synthes in 2011 at 5.4 times sales could be used as ..... prodigious overseas cash balance at that time), but Synthes offered higher operating margins in the mid-30s

  6. Johnson & Johnson Posts Solid 2Q, Buoyed by New Drug Launches and Return of Several OTC Products

    Commentary

    Tue, 16 Jul 2013

    Johnson & Johnson JNJ reported second-quarter results largely in line with our expectations ..... drag on this part of J&J's portfolio. Excluding the acquisition of Synthes and other portfolio changes, J&J's device segment was flat year

  7. J&J Posts Solid 4Q Results, but Offers Weak Outlook for 2013

    Commentary

    Tue, 22 Jan 2013

    inflection point for Johnson & Johnson , and we see the ..... device side, the Synthes acquisition not ..... from the recent Synthes acquisition, Johnson & Johnson posted 4% year-over-year ..... period, with the Synthes acquisition providing

  8. J&J Posts 3Q Results Slightly Shy of Our Expectations, but Strong Long-Term Outlook Intact

    Commentary

    Tue, 16 Oct 2012

    Johnson & Johnson JNJ reported third-quarter results slightly below our expectations ..... increased operationally 10.8% year over year as the recently completed Synthes acquisition added 5.8% to growth. This 5% underlying growth represented

  9. Mild Winter Decelerates Synthes Growth, J&J Offer Extended

    Commentary

    Wed, 25 Apr 2012

    Sates and Europe cut into Synthes ' SYST growth rate in recent months. In the first quarter, Synthes sales only grew 2% in local ..... that geographic region. Synthes also continues to expand ..... overshadowed by a mild winter, Synthes ' emerging market growth ..... intact. We still expect Johnson & Johnson JNJ to benefit from those

  10. Johnson & Johnson Picks Head of Devices Segment to Take Over for Retiring CEO

    Commentary

    Wed, 22 Feb 2012

    Johnson & Johnson JNJ announced William ..... the integration of Synthes , the device business ..... the group chairman of Johnson & Johnson 's pharmaceutical ..... Africa. He briefly left Johnson & Johnson to run Novartis' North

« Prev12Next »
Content Partners